Literature DB >> 9482679

Tumor angiogenesis--a new therapeutic target in gliomas.

E L Lund1, M Spang-Thomsen, H Skovgaard-Poulsen, P E Kristjansen.   

Abstract

Tumor growth is critically dependent on angiogenesis, which is sprouting of new vessels from pre-existing vasculature. This process is regulated by inducers and inhibitors released from tumor cells, endothelial cells, and macrophages. Brain tumors, especially glioblastoma multiforme, have significant angiogenic activity primarily by the expression of the angiogenic factor VEGF Anti-angiogenic therapy represents a new promising therapeutic modality in solid tumors. Several agents are currently under evaluation in clinical trials. The present review describes the principal inducers and inhibitors of angiogenesis in tumors and summarizes what is known about their mechanisms of action in relation to CNS tumors. Potential areas for clinical use are also discussed.

Entities:  

Mesh:

Year:  1998        PMID: 9482679     DOI: 10.1111/j.1600-0404.1998.tb00609.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  18 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  The role of CXC chemokines in pulmonary fibrosis.

Authors:  Robert M Strieter; Brigitte N Gomperts; Michael P Keane
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas.

Authors:  P E Kish; M Blaivas; M Strawderman; K M Muraszko; D A Ross; B D Ross; G McMahon
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

4.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.

Authors:  Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

5.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Role of perfusion CT in glioma grading and comparison with conventional MR imaging features.

Authors:  S K Ellika; R Jain; S C Patel; L Scarpace; L R Schultz; J P Rock; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-24       Impact factor: 3.825

Review 8.  Renin angiotensin system and its role in biomarkers and treatment in gliomas.

Authors:  Alexander Perdomo-Pantoja; Sonia Iliana Mejía-Pérez; Liliana Gómez-Flores-Ramos; Montserrat Lara-Velazquez; Cordelia Orillac; Juan Luis Gómez-Amador; Talia Wegman-Ostrosky
Journal:  J Neurooncol       Date:  2018-02-16       Impact factor: 4.130

9.  Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.

Authors:  Yan Li; Janine M Lupo; Rupa Parvataneni; Kathleen R Lamborn; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

10.  Drug-induced apoptosis by a matrix metalloproteinase inhibitor, SI-27 on human malignant glioma cell lines; in vitro study.

Authors:  Ryuzaburo Kanazawa; Daizo Yoshida; Hiroshi Takahashi; Yuichi Sugisaki; Satoru Suzuki; Akira Teramoto
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.